FLT3 and leukemia: Indeed, about 75% of patients with FLT3-ITD–mutated AML at diagnosis continue to have the ITD mutation at relapse [22], suggesting that FLT3-ITD may function as the driver mutation responsible for progressing the disease into overt leukemia.